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Hippocampal network activity is predominantly coordinated by γ-amino-butyric acid
(GABA)ergic neurons. We have previously hypothesized that the altered excitability
of hippocampal neurons in Alzheimer’s disease (AD), which manifests as increased
in vivo susceptibility to seizures in the TgCRND8 mouse model of AD, may be
related to disruption of hippocampal GABAergic neurons. In agreement, our previous
study in TgCRND8 mice has shown that hippocampal GABAergic neurons are more
vulnerable to AD-related neuropathology than other types of neurons. To further
explore the mechanisms behind the observed decrease of GABAergic neurons in 6
month-old TgCRND8 mice, we assessed the relative proportion of somatostatin (SOM),
neuropeptide Y (NPY) and paravalbumin (PV) sub-types of GABAergic neurons at the
regional and sub-regional level of the hippocampus. We found that NPY expressing
GABAergic neurons were the most affected, as they were decreased in CA1-CA2
(pyramidal-, stratum oriens, stratum radiatum and molecular layers), CA3 (specifically
in the stratum oriens) and dentate gyrus (specifically in the polymorphic layer) in
TgCRND8 mice as compared to non-transgenic controls. SOM expressing GABAergic
neurons were decreased in CA1-CA2 (specifically in the stratum oriens) and in the
stratum radiatum of CA3, whereas PV neurons were significantly altered in stratum
oriens sub-region of CA3. Taken together, these data provide new evidence for the
relevance of hippocampal GABAergic neuronal network disruption as a mechanism
underlying AD sequelae such as aberrant neuronal excitability, and further point to
complex hippocampal regional and sub-regional variation in susceptibility to AD-related
neuronal loss.
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Introduction
Alzheimer’s disease (AD) is an age-related neurodegenerative dis-
order characterized by progressive loss of cognitive and executive
functions. The main histological hallmarks of AD are the extra-
cellular deposition of amyloid beta (Aβ) peptides into the extra-
cellular amyloid-plaques and the intracellular accumulation of
hyperphosphorylated tau protein (neurofibrillary tangles) (Hardy
and Selkoe, 2002; Hardy, 2006). Clinically, the disease manifests
first by cognitive complaints at a stage considered as a prodromal
(silent) phase of AD, also known as MCI (mild cognitive impair-
ment). For the reasons that remain unknown, not all of sub-
jects with MCI will convert to AD (Nelson and O’Connor, 2008)
with a “probable” clinical diagnosis based mainly on PET-scan
imaging of Aβ accumulation into amyloid-plaques and elevated
Aβ42/Aβ40 ratio in cerebrospinal fluid. At the time of diagno-
sis, significant hippocampal atrophy is already detectable in some
patients. As AD progresses, the neuronal loss increases, yield-
ing a significant neurodegeneration which is generally observed
at the terminal stages in post-mortem studies (McKhann et al.,
1984).
We and others have previously reported a loss of hippocam-
pal GABAergic neurons in 6 month-old mice in AD models
such as AβPPdE9 (Ramos et al., 2006) and TgCRND8 (Krantic
et al., 2012). Remarkably, the TgCRND8 mice used in our stud-
ies display synaptic hyperexcitability in the CA1 hippocampal
region, which is detectable at 5 months (Jolas et al., 2002). More-
over, in vivo treatment of 1.5–2 month-old TgCRND8 mice with
pentylenetetrazole, a drug acting on the picrotoxin site of type-A
GABA receptors, has revealed latent GABA-related hippocampal
network impairments (Del Vecchio et al., 2004). These findings
strongly support the recently-proposed hypothesis that epilepti-
form activity is the cause, rather than a consequence, of neurode-
generation in AD (Palop et al., 2007; Gleichmann et al., 2011).
According to this hypothesis, the Aβ-mediated increase in hip-
pocampal network excitability is associated with increased global
excitatory activity, with subsequent negative impact on learning
and memory (Palop et al., 2007; Palop and Mucke, 2009).
Phenotypic analysis of hippocampal GABAergic neuronal
populations at the overt stages of AD has pointed to selective
loss in number or function of their specific sub-types, notably
neurons expressing somatostatin (SOM), neuropeptide Y (NPY)
(Ramos et al., 2006) and paravalbumin (PV) (Verret et al., 2012).
These studies have reported some regional selectivity of SOM
neuronal loss, with stratum oriens in CA- and hilar perforant
path-associated NPY neurons in the dentate gyrus (DG) being
the most vulnerable (Ramos et al., 2006). However, the putative
sub-regional differences regarding respective layers of SOM and
NPY vulnerability to Aβ have not been explored in detail. These
GABAergic neurons in CA stratum oriens and DG hilus are cen-
trally involved in the innervation of the distal dendritic arbor of
pyramidal and granular neurons (Maccaferri and Lacaille, 2003)
Abbreviations: Aβ, Amyloid beta; AD, Alzheimer’s disease; CA, Cornu ammo-
nis; DG, dentate gyrus; GABA, γ-aminobutyric acid; GR, granule cell layer; MO,
molecular layer; NPY, neuropeptide Y; PO, polymorphic layer; PV, parvalbumin;
PY, pyramidal layer; SO, stratum oriens; SOM, somatostatin; SR, stratum radiatum.
and fire at theta (4–10Hz) frequency (Klausberger et al., 2003,
2004), suggesting their involvement in generation of endogenous
theta oscilations. In addition to CA1, CA3, and DG, the subicu-
lum also contains an endogenous generator of theta oscillatory
activity (Goutagny et al., 2009; Jackson et al., 2014). In contrast
to CA1 and CA3, where low (approximately 40–80Hz) and high
(around 120–160Hz) gamma oscillations are not found intrinsi-
cally, these are both generated in the subiculum (Goutagny et al.,
2009). Given that gamma oscillations are critically controlled
by GABAergic interneurons, that they are embedded into theta
rhythm, and that this gamma-theta coupling is crucial for learn-
ing and memory (Goutagny et al., 2009), the putative alterations
of SOM and NPY GABAergic neurons in the subiculum may be
critical in AD. In this study, we therefore asked whether SOM-,
NPY-, and PV-expressing GABAergic neurons are selectively lost
in specific regions (CA1/CA2, CA3, dentate gyrus, and subicu-
lum) and sub-regions (respective layers) of the hippocampus in 6
month-old TgCRND8 mouse. This age was chosen based on our
previous study showing that the overall population of GABAergic
neurons in TgCRND8 mice is first decreased in hippocampal CA
regions at this age (Krantic et al., 2012).
Materials and Methods
Animals
TgCRND8mice bear Swedish KM670/671NL and Indiana V717F
mutations in the Aβ precursor encoding gene. By 3–4 months,
they overexpress human Aβ, encoded by a double mutated form
of hAβAPP (695 Swedish KM670/671NL and Indiana V717F
APP mutations) transgene. Memory deficits and Aβ pathology
progress during the course of aging, and 6 month-old TgCRND8
mice have a high Aβ level and severe plaque load in many brain
regions, including the hippocampus (Chishti et al., 2001).
All experiments followed the policies and guidelines of the
Canadian Council on Animal Care, the Animal Care regulations
of the McGill University, guidelines on the use of laboratory ani-
mals and the U.S. National Institutes of Health Guide for the Care
and Use of Laboratory Animals. Male TgCRND8 and wild-type
(WT) mice were maintained on an outbred C3H/C57BL6 back-
ground and kept on a 12 h light/dark cycle with food and water
ad libitum.
Immunohistochemistry on Free-Floating Sections
Animals (n = 3 per experimental group) were transcardially
perfused (PBS followed by 4% PFA), and brains were stored
in fixative for 24 h at 4◦C, then in a sucrose solution (30% in
PBS) for 3 days at 4◦C, frozen using dimethylbutane and stored
at −80◦C. Brains were sliced coronally using a freezing micro-
tome at 40µm, and free-floating sections were stored in a cryop-
reservative solution (3:3:4 glycerol:ethylene glycol:PBS) at−20◦C
in preparation for immunohistochemistry (IHC) staining. Sec-
tions (serial sectioning fraction = 1/8) were incubated in PBS
with 0.2% Triton X–100 for 1.5 h, followed by 3%H2O2 prepared
in PBS for 10min. The sections were blocked with 2% normal
serum in PBS + 0.2% Triton X–100 for 1 h. Primary antibodies
(Millipore; SOM: rabbit, 1:1000, Millipore; NPY: rabbit, 1:2000,
Abcam; PV: rabbit, 1:5000, Abcam) were applied overnight at
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4◦C. The immunolabeled product was visualized by using the
avidin-biotin complex method (Vectastain elite ABC Kit, Vec-
tor Laboratories; 30min), with IgG conjugate (1 h), followed by
DAB (for SOM) or SG (for NPY and PV) chromogen devel-
opment (DAKO). The stained sections were mounted on slides
(dried overnight), dehydrated in ethanol, cleared in xylene, and
coverslipped.
Cell Quantification
Immunoreactive (IR) cell somata were counted in each hip-
pocampal region and subregion (from bregma −1.06mm to
bregma −3.88mm, Franklin and Paxinos, 2007), on a Nikon
Eclipse E600 (Kanagawa, Japan) with a 20X objective, by an
experimenter blind to group identity. Anatomical regions were
determined as per Franklin and Paxinos (2007). CA1 and CA2
were combined (CA1/2) due to the relatively amorphous bound-
ary separating these two regions. Intrasubject counts by an addi-
tional experimenter (on a Leica DM 2500 microscope) of an
additional marker to confirm count/total accuracy correlated sig-
nificantly (p = 0.0062), with Pearson r and intraclass correla-
tion values >0.5. Quantification is shown as cells per section.
Pairwise comparisons betweenWT and Tg animals in hippocam-
pal regions and subregions were performed using unpaired t-
tests, with Welch’s correction applied when required due to data
variance. P < 0.05 were considered significant.
Results
Regional and Sub-Regional Distribution of
NPY-Expressing Neurons
NPY-IR cells were observed in all CA regions (CA1/CA2, CA3),
the DG, and the subiculum of the hippocampal formation of
FIGURE 1 | Micrographs of immunohistochemical labeling of
interneurons for parvalbumin (PV), neuropeptide Y (NPY), and
somatostatin (SOM) in the CA1 and 2, CA3, dentate gyrus (DG), and
subiculum (SUB) hippocampal regions. Scale bar = 50µm.
6 month-old TgCRND8 mice (Figure 1; relative proportions
are shown in Figure 2I). This immunoreactivity was very sim-
ilar, as per visual inspection, to those observed in anatomi-
cally matched hippocampal sections of the WT littermates. In
contrast, quantification of NPY-IR neurons in the hippocam-
pus as a whole indicated a considerable decrease in their total
number in TgCRND8 mice compared to aged-matched WT
controls (p = 0.0004; Figure 2A). This loss appeared to be
distributed throughout hippocampal regions, including CA1/2
(p = 0.0011; Figure 2B), CA3 (p = 0.012; Figure 2C), and
DG (p = 0.022; Figure 2D), but not subiculum (p = 0.22;
Figure 2E).
Sub-regional analyses revealed that the CA1/2 was affected
throughout the region. Indeed, the pyramidal layer (p = 0.0045),
stratum oriens (p = 0.022), and stratum radiatum (p = 0.037)
(but not the molecular layer; p = 0.095) displayed a decreased
number of NPY-IR neurons in TgCRND8 mice as compared to
controls (Figure 2F). The loss of NPY-IR neurons in the CA3
region likely reflects the loss of these neurons in the stratum
oriens layer (p = 0.013; Figure 2G), as the pyramidal layer (p =
0.10) and stratum radiatum (p = 0.42) were not significantly
affected.
In the DG, the decrease in the number of NPY-IR neu-
rons in TgCRND8 mice may be attributed to a selective
loss in the polymorphic layer (p = 0.013), as the granu-
lar (p = 0.49) and molecular (p = 0.50) DG layers were
not significantly affected in Tg mice compared to WT controls
(Figure 2H).
Regional and Sub-Regional Distribution of PV-
and SOM-Expressing Neurons
PV- and SOM-IR cells were observed in CA1/2, CA3, DG
and subiculum in 6 month-old TgCRND8 mice (Figure 1;
relative proportions are shown in Figures 3I, 4H, respec-
tively), and their distribution was similar to that seen
in anatomically matched hippocampal sections of the WT
littermates.
PV-IR neurons in the hippocampus did not differ by geno-
type, either overall (p = 0.37; Figure 3A) or in CA1/2 (p = 0.84;
Figure 3B) or CA3 (p = 0.21; Figure 3C), DG (p = 0.15;
Figure 3D), or subiculum (p = 0.65; Figure 3E). Examining
hippocampal subregions also revealed a lack of effect in CA1/2
pyramidal layer (p = 0.97), stratum oriens (p = 0.91), and
stratum radiatum (p = 0.39; Figure 3F), CA1/3 pyramidal layer
(p = 0.29), stratum oriens (p = 0.07), and stratum radiatum
(p = 0.33; Figure 3G), and DG polymorphic layer (p = 0.15),
granule cell layer (p = 0.22), and molecular layer (p = 0.15;
Figure 3H).
Regarding SOM-IR cells, a significant decrease was observed
both overall (p = 0.049; Figure 4A) and in CA1/2 (p = 0.040;
Figure 4B). CA3 (p = 0.074; Figure 4C), DG (p = 0.29;
Figure 4D), and subiculum (p = 0.30; Figure 4E) were not sig-
nificantly affected. Concerning the layers of the CA regions, a
significant decrease was observed in CA1/2 stratum oriens (p =
0.041; Figure 4F) and the CA3 stratum radiatum (p = 0.012;
Figure 4G), but not CA1/2 stratum radiatum (p = 0.19) or CA3
stratum oriens (p = 0.35).
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FIGURE 2 | Quantification of neuropeptide Y- (NPY)-immunoreactive
(IR) cells in the overall hippocampus (A), CA1 and CA2 (B), CA3 (C),
dentate gyrus (DG; D) and subiculum (E), and in subregions within
CA1 and CA2 (F), CA3 (G), and DG, (H). (I) subregional proportion of
NPY-IR cells within hippocampal regions, for wild-type (WT) and transgenic
(Tg) animals. PY, pyramidal layer; SO, stratum oriens; SR, stratum radiatum;
MO, molecular layer; PO, polymorphic layer; GR, granule cell layer. WT,
wild-type; Tg, transgenic. *p < 0.05; **p < 0.01; ***p < 0.001.
FIGURE 3 | Quantification of parvalbumin- (PV)-immunoreactive (IR)
cells in the overall hippocampus (A), CA1 and CA2 (B), CA3 (C),
dentate gyrus (DG; D) and subiculum (E), and in subregions within
CA1 and CA2 (F), CA3 (G), and DG (H). (I) subregional proportion of PV-IR
cells within hippocampal regions, for wild-type (WT) and transgenic (Tg)
animals. PY, pyramidal layer; SO, stratum oriens; SR, stratum radiatum; MO,
molecular layer; PO, polymorphic layer; GR, granule cell layer. WT, wild-type;
Tg, transgenic.
Discussion
The principal finding of this study is that different hippocampal
GABAergic neurons display remarkably distinct regional and
sub-regional vulnerability to Aβ accumulation. Notably, in
6 month-old TgCRND8 mice, NPY-expressing GABAergic
neurons are significantly decreased in all studied hippocampal
regions except the subiculum. Regarding sub-regions, stratum
oriens in CA is generally affected overall, as significantly fewer
NPY neurons were found both in CA1/2 and CA3. Interestingly,
SOM-expressing neurons of the stratum oriens were also found
to be more vulnerable globally than in other layers of CA1/2,
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FIGURE 4 | Quantification of somatostatin- (SOM)-immunoreactive
(IR) cells in the overall hippocampus (A), CA1 and CA2 (B),
CA3 (C), dentate gyrus (DG; D) and subiculum (E), and in
subregions within CA1 and CA2 (F), and CA3 (G).
(H) subregional proportion of SOM-IR cells within hippocampal
regions, for wild-type (WT) and transgenic (Tg) animals. SO, stratum
oriens; SR, stratum radiatum; PO, polymorphic layer. WT, wild-type;
Tg, transgenic. *p < 0.05.
suggesting that this layer is a particular locus of AD-related
GABAergic vulnerability. In addition, in the CA3 stratum radia-
tum layer, TgCRND8 showed fewer SOM- but not PV- or NPY-
expressing neurons, suggesting that vulnerability in this region
is neuronal subtype-specific to SOM-expressing neurons. Finally,
overall hippocampal PV-expressing neurons demonstrated less
vulnerability to the TgCRND8 AD model than other GABAergic
neurons. The reasons for this apparent resistance of PV- com-
pared to NPY- and SOM-expressing GABArgic neurons remain
unknown. An interesting hypothesis is that PV-expressing neu-
rons in the studied hippocampal sub-regions may be less active
than NPY- and SOM-expressing neurons. This hypothesis will
likely become testable in the near future, for example by combin-
ing electrophysiology and optogentics to functionally distinguish
between these subtypes of GABAergic neurons. Importantly,
recent studies have pointed also to a lower vulnerability of PV-
expressing neurons in comparison to other types of GABAergic
neurons. For instance, decrease in PV-expressing neurons occurs
later and is less pronounced in the course of AD-like pathology
than the loss of other types of GABAergic neurons (e.g., SOM-
or calretinin-expressing neurons) in both olfactory bulb (Saiz-
Sanchez et al., 2013) and olfactory cortex (Saiz-Sanchez et al.,
2012) of the APPxPS1 mice. Similarly, PV-expressing neurons
in the frontal cortex of APP/PS1 knock-in mice bearing dou-
ble mutation in APP and PS1 display a relative resistance to
Aβ accumulation; in spite of a 34% decrease in the total num-
ber of neurons between 10 and 2 month-old mice, the num-
ber of PV-expressing neurons was unchanged between the two
ages (Lemmens et al., 2011). Moreover, in post-mortem brains of
AD patients, PV-expressing neurons were found to be increased
in the piriform cortex, whereas SOM- and calretinin GABAer-
gic neurons were decreased (Saiz-Sanchez et al., 2014). Alto-
gether, these data support relative resistance of PV-expressing
GABAergic neurons to AD pathology.
These findings confirm and further extend our previous data
on the significant loss of GABAergic neurons in CA regions
of 6 month-old TgCRND8 AD-modeling mice (Krantic et al.,
2012). They are also in agreement with the previous study by
Ramos et al. (2006) concerning the sub-types of the most affected
GABAergic neurons. This previous study has reported that NPY
and SOM neurons are the most vulnerable in stratum oriens-
lacunosum moleculare in CA regions of APP/PS1 at 6 months of
age. In addition, we found a significant decrease of NPY neurons
in dentate gyrus of TgCRND8mice, similar to the loss reported in
hilar performant path-associated cells (Ramos et al., 2006). How-
ever, in contrast to the APP/PS1 mice (Ramos et al., 2006), the
decrease of NPY-IR cells contributes significantly to the observed
loss of neurons in pyramidal layer of the CA1/CA2 region.
Regarding SOM neurons in stratum oriens, the loss we
observed in 6 month-old TgCRND8 mice likely has a major
impact in terms of GABAergic control of neuronal excitability,
as all neurons of stratum oriens are GABAergic (Freund and
Buzsaki, 1996). This is in line with what has been previously
suggested for APP/PS1 mice (Ramos et al., 2006). However, in
contrast to this study, we did not observe a significant decrease of
SOM neurons in the dentate gyrus of TgCRND8 mice. In addi-
tion to SOM-expressing neurons, PV-expressing neurons were
also unaffected in the DG, as were all studied GABA-expressing
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neuronal types in the subiculum. To our knowledge, this is
the first such investigation of the subiculum, as this hippocam-
pal sub-region has not been studied previously in terms of
GABAergic neuronal vulnerability to Aβ. The relative resistance
of the studied GABAergic neurons in the subiculum of 6 month-
old TgCRND8 mice is intriguing. Indeed, the subiculum con-
tains endogenous generator of hippocampal oscillatory activity
(Goutagny et al., 2009; Jackson et al., 2014) which have been
shown to be altered from the earliest stages of AD pathology in
TgCRND8 mice (Goutagny et al., 2013).
Regarding PV neurons, our data differ from those provided
by a previous study that pointed to a significant loss of these
neurons in the CA1/2 region of APP/PS1 mice (Takahashi et al.,
2010). The difference between our studies is likely due to the dif-
ferent age of the mice: 6 months for TgCRND8 and 10 months
for APP/PS1 mice. It is less likely that the differences between
our studies may come from the use of distinct mice strains bear-
ing different mutations, as the pattern of the studied GABAergic
neurons in the two transgenic ADmousemodels appears globally
similar. For instance, NPY neurons in the stratum oriens of both
APP/PS1 (Ramos et al., 2006) and TgCRND8 (present study)
strains are vulnerable to Aβ as compared to the non-transgenic
animals.
The primary question raised by the observed alterations in the
composition of the hippocampal population of the GABAergic
neurons is how this functionally impacts neuronal excitability.
In this light, the loss of SOM and NPY neurons in the stratum
oriens of the CA1 region likely has major consequences in terms
of control of pyramidal cell excitability. Indeed, cells in stratum
oriens project to distal dendrites of CA1 pyramidal cells that pro-
vide dendritic inhibition (Maccaferri and Lacaille, 2003). As a
corollary, dendritic inhibition may be reduced due to the loss
of GABAergic neurons in the stratum oriens of the CA1 region
with a subsequent dysregulation of entorhinal cortex input to
CA1. Interestingly, a similar loss of SOM interneurons without
alteration of PV neurons in the stratum oriens of CA1 has been
reported in aged rat hippocampus and related to age-associated
seizures and cognitive impairments (Stanley et al., 2012).
In conclusion, it is currently clear that the control of neu-
ronal excitability through the control of GABAergic inhibitory
input should be considered a therapeutic option for AD. In agree-
ment, a number of studies using anti-epileptic drugs, likely acting
through potentiation of GABAergic neurotransmission such as
levetiracetam or topiramate, have reported beneficial effects on
neuropathology and cognitive impairments in mouse AD mod-
els (Sanchez et al., 2012; Devi and Ohno, 2013; Shi et al., 2013;
Zhang et al., 2014). Most importantly, levetiracetam has proven
efficient in the management of not only spontaneous epilepti-
form activity, which accompanies the early stages of AD (Vos-
sel et al., 2013), but also in improving cognition (Bakker et al.,
2012). These exciting recent advances should foster further clin-
ical assays for shared therapeutic options based on the use of
anti-epileptic drugs to halt AD-associated cognitive impairment.
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